EuroBiotech: More Articles of Note


> ImmunOs raised CHF 15 million ($15 million) to complete first-in-human trials of a cancer drug. Pfizer Ventures co-led the series A with BioMedPartners. Release 

> Genmab shared early data on its CD3xCD20 bispecific. With dose escalation still ongoing, Genmab has seen a 37% response rate. Statement 

> Oryzon presented updated data on iadademstat in acute myeloid leukaemia. Three-quarters of patients have responded to the drug. Release 


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Newron Pharmaceuticals delayed a readout from its phase 3 Rett syndrome trial. Analysts were expecting the data to drop imminently, but the results will remain blinded until after a meeting with the FDA. Statement 

> Oncopeptides published updated pivotal data on melflufen in multiple myeloma. The Swedish company is expected to file for approval next year. Release 

> Bioncotech Therapeutics detailed plans to test BO-112 in combination with Keytruda. Statement 

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.